Kairui Medical

Kairui Medical (also known as Aixam) develops intelligent blood collection robots that combine infrared imaging, ultrasound technology, and AI algorithms to automate venous blood sampling. Founded in Chengdu’s Tianfu International Bio-Town in 2022, the company has achieved a 95% success rate in animal experiments—surpassing the previously reported international benchmark of 83.9%.

Company Overview

Kairui Medical was established by founder Wang Yigang, who brought over 20 years of medical device industry experience to the venture. The founding team identified blood collection as a high-frequency, repetitive task representing approximately 70% of diagnostic decision-making in clinical settings. China performs an estimated 16 million venous blood draws daily, creating substantial demand for automation solutions.

The company completed its Pre-A financing round in June 2025, led by Luzhou Shuanggang Industrial Investment Development Co., a regional industrial investment platform. Proceeds are directed toward R&D acceleration, production line construction, talent acquisition, and CE marking preparation.

Core team members include co-founder Chen Ke (Vice General Manager), Dr. Jing Shuaiqi (PhD from UESTC specializing in computer science), and Wang Qiulin (Tsinghua University graduate with expertise in medical imaging algorithms). The R&D team spans imaging, electronics, control systems, mechanical engineering, software, and biomedical disciplines, with 90% holding graduate degrees from institutions including Tsinghua University and the University of Electronic Science and Technology of China.

Core Products

M1pro Intelligent Blood Collection Robot

The flagship M1pro system represents Kairui Medical’s core commercialization effort. Key specifications include:

• Imaging: Dual-mode infrared and ultrasound fusion for 3D vessel reconstruction
• Manipulation: Nine-axis robotic arm with proprietary tri-axial concentric mechanism
• Precision: Operational accuracy of 0.07mm, probe tolerance of 0.05mm
• Coverage: Full age-range capability from neonates to elderly patients
• Cycle time: Approximately 90 seconds per complete blood draw

The system has completed type testing and entered multi-center clinical trials at West China Hospital, Sichuan Provincial Women’s and Children’s Hospital, and Sichuan Provincial Cancer Hospital. Nearly 300 clinical cases have been completed, with Class III medical device registration anticipated in the near term.

M1mini Portable Blood Collection Robot

A compact version under development targeting mobile healthcare scenarios, community clinics, and point-of-care applications.

Ultrasound Intelligent Diagnostic Robot

A pre-research product combining blood sampling with diagnostic capabilities. The system eliminates traditional coupling gel requirements through proprietary coupling sleeves and generates 3D visualization results more rapidly than conventional ultrasound.

Technology & Innovation

Kairui Medical’s technical approach addresses two fundamental challenges in automated phlebotomy: vessel visualization (“seeing”) and needle placement accuracy (“targeting”).

Vessel Imaging Technology The proprietary “Fire Eye” system employs binocular infrared combined with ultrasound fusion to construct three-dimensional vascular maps. This dual-modality approach provides both surface mapping (infrared) and depth information (ultrasound), enabling reliable targeting of vessels as small as 0.5mm in diameter.

Precision Control System The “Divine Needle” series incorporates a nine-axis robotic arm with tri-axial concentric design that compensates for motion errors at each joint. The system achieves puncture accuracy within 0.07mm—equivalent to targeting a human hair from 100 meters, according to company descriptions.

AI Decision Engine Machine learning algorithms analyze optical-acoustic images, force feedback, and biological parameters to determine optimal puncture path, depth, force, and velocity. Real-time navigation during insertion corrects for potential deviation.

Research findings were published at ICRA 2025 (IEEE International Conference on Robotics and Automation), demonstrating 95% success rate in animal experiments involving rat tail veins with diameters averaging 0.61mm—vessels comparable to neonatal arm veins.

Market Presence

Kairui Medical operates from Chengdu’s Tianfu International Bio-Town in the Gaoxin District. The company has established clinical collaboration relationships with several major Sichuan healthcare institutions for product validation and iteration.

The broader market opportunity is substantial: China’s estimated 16 million daily blood draws translate to potential demand for approximately 140,000 automated blood collection units, representing an 80+ billion RMB market at estimated unit prices of 600,000 RMB.

Global competitors include Netherlands-based Vitestro (CE marked August 2024, 95% first-stick success in clinical trials) and Beijing-based MagicNurse (first company globally to obtain Class III registration for intelligent blood collection). Kairui Medical positions itself as potentially the third company worldwide to achieve regulatory approval in this category.

Key Milestones

• 2022: Company founded in Chengdu Tianfu International Bio-Town
• 2023: Formal operations commenced
• 2024: Animal experiments achieved 95% success rate; ICRA publication
• 2025: Completed Pre-A financing round; M1pro entered clinical trials
• 2025: National Innovative Medical Device application submitted
• 2025: Class III medical device registration process initiated

Frequently Asked Questions

What makes Kairui Medical’s blood collection robot different from competitors?

The M1pro combines dual-modality imaging (infrared + ultrasound) with a proprietary tri-axial concentric mechanism achieving 0.07mm precision. The system covers all age groups including neonates, whereas many competing systems have age restrictions.

Has the M1pro received regulatory approval?

As of early 2026, the M1pro has completed type testing and is in multi-center clinical trials. Class III NMPA registration is anticipated in the near term. The company is also preparing CE marking applications for European market entry.

What clinical applications does the blood collection robot serve?

Primary applications include routine venous blood sampling in hospital laboratories, physical examination centers, and outpatient clinics. Future product roadmap includes integration of blood collection with diagnostic analysis for point-of-care testing scenarios.